Apogee Therapeutics, Inc. (APGE) Stock Price & How to Invest

Apogee Therapeutics was founded in 2022 and went public in July 2023, and it runs on a single engineering premise: take inflammation and immunology targets that are already clinically validated, then re-build the antibody so it stays in the body far longer. The point is dosing interval. Existing biologics for atopic dermatitis are typically injected every two weeks, and Apogee's half-life-extended molecules are designed for quarterly or even less frequent maintenance dosing. The lead program is zumilokibart (APG777), an anti-IL-13 monoclonal antibody. Its Phase 2 APEX trial in atopic dermatitis read out positive 52-week Part A data in March 2026 and then positive 16-week Part B induction data on May 27, 2026, where about 65.9% of mid-dose patients reached EASI-75 against roughly 23.4% on placebo, with all primary and secondary endpoints met. Behind it sit APG990 (anti-OX40L), the APG279 combination of APG777 plus APG990 in Phase 1 with proof-of-concept data guided for the second half of 2026, APG808 (anti-IL-4Ra) in Phase 1b for asthma, and preclinical APG333 (anti-TSLP). The company has roughly 261 employees in Waltham, Massachusetts, and no product revenue.

The investment picture changed completely on June 22, 2026. Before that, Apogee was funding itself the way clinical-stage biotech usually does: a $403 million upsized equity offering priced at $70 a share in March 2026, followed on May 27 by a strategic financing collaboration with Blackstone Life Sciences worth up to $1.3 billion in non-dilutive capital (about $800 million of synthetic royalty funding plus up to $500 million of senior debt) to carry zumilokibart into Phase 3. Cash, equivalents and marketable securities stood at roughly $1.3 billion at March 31, 2026, against about $8 million of debt, with management guiding a runway into 2029. Then AbbVie agreed to acquire the company for $135.11 a share in cash, valuing Apogee at approximately $10.9 billion in total equity value, and the stock jumped about 46.8% in a day to roughly $132.64 from a pre-announcement level near $90. The transaction is a one-step merger, the special meeting is set for August 11, 2026, closing is expected in the third quarter of 2026, and AbbVie has said it expects the deal to be accretive to adjusted diluted EPS beginning in 2032. The arithmetic that matters for a holder today is the spread and the probability of close, not the Phase 3 readout.

The dominant risk is binary and no longer scientific: if the merger fails to close, the reference point is the pre-announcement price near $90, roughly a third below where shares trade today, and possibly lower given how much event-driven capital has rotated in. The compensation for carrying that risk is small, since the gross spread has compressed to roughly half a percent. On a standalone basis Apogee has no revenue, posted a net loss of about $74.1 million in the first quarter of 2026 on roughly $60.8 million of R&D spending, and had not yet started the Phase 3 program that would decide the company's value. The atopic dermatitis field is crowded and well funded, led by Dupixent and including AbbVie's own Rinvoq, so a standalone Apogee would be entering a commercial fight against entrenched incumbents. Several plaintiffs' firms have announced routine merger-adequacy and disclosure investigations, which are common in deals of this size and are distinct from securities fraud class actions; no active securities fraud class action was identified. If the deal does close, the shares are cancelled for cash and delisted, so the position converts to cash on a timeline the holder does not control.

12 analysts publish price targets on APGE, averaging $130.53 against a $134.49 price as of August 2026, or -2.9%. The published targets run from $81.00 to $137.00, a moderate spread, and the ratings split 3 buy, 12 hold, 0 sell. Over the last six months there have been 8 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full APGE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Apogee Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The AbbVie cash price is now the ceiling. AbbVie agreed to pay $135.11 a share in cash, a fixed number with no equity component and no publicly disclosed contingent value right, so good news from the pipeline no longer raises the payout. The most optimistic published target, $137.00, assumes this works close to its best case.

The case against. The dominant risk is binary and no longer scientific: if the merger fails to close, the reference point is the pre-announcement price near $90, roughly a third below where shares trade today, and possibly lower given how much event-driven capital has rotated in. The most pessimistic target, $81.00, is roughly what APGE is worth if this bites instead.

Read the full bull and bear case on APGE, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Apogee Therapeutics, Inc.'s investor relations page or your broker.

• Cash, equivalents and marketable securities: ~$1.3 billion at March 31, 2026, versus ~$902.9 million at year-end 2025
• Cash runway: Guided into 2029, before drawing the Blackstone facility of up to ~$1.3 billion
• R&D expense (Q1 2026): ~$60.8 million, the bulk of operating spend
• Net loss: ~$74.1 million in Q1 2026 (versus ~$55.3 million a year earlier), ~$274 million trailing twelve months
• Revenue: None. Apogee is pre-commercial with no approved products
• Market cap vs deal price: ~$10.1 billion at ~$134.49 a share, against AbbVie's $135.11 cash price (~$10.9 billion equity value)

Conventional valuation multiples do not apply here twice over: Apogee has no revenue and no earnings to anchor a multiple, and the price is contractually pinned to a cash offer rather than set by fundamentals. The relevant number is the spread, roughly 0.5% between the $134.49 quote and the $135.11 price, which is the market's implied compensation for the risk that the August 11 vote or regulatory clearance does not go as expected. For reference, shares changed hands at $70 in the March 2026 equity offering and near $90 just before the deal was announced, so the balance sheet and pipeline supported far less than the current quote.

If you want APGE exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to APGE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get APGE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (XBI), which spreads the position across many companies. Or build it into a focused thematic portfolio, so APGE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where APGE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Apogee is a real clinical-stage immunology company whose lead antibody worked in Phase 2, but at roughly $134.49 against a fixed $135.11 cash price the shares now price deal completion rather than drug development.

Whether APGE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is APGE a buy or a sell?, and where the stock could go from here in the APGE stock forecast.

For income investors, whether APGE pays a dividend and how the payout looks is covered in does APGE pay a dividend? And to weigh APGE against a peer, read the full side-by-side comparisons: APGE vs SNY and APGE vs REGN.